Metsera, Inc.
MTSRHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$224.8M | −$43.7M |
| Net income | −$209.1M | −$47.2M |
| Total assets | $451.0M | $168.8M |
| Total liabilities | $163.6M | $70.3M |
| Equity | −$253.5M | −$45.2M |
| EPS (diluted) | $-14.49 | $-3.48 |
| Shares out. | 15.4M | 13.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- —
- Net margin
- —
- Return on equity
- 82.5%
- Return on assets
- −46.4%
- Return on capital (ROCE)
- −58.6%
- Liabilities / assets
- 36.3%
- Debt / equity
- —
- Book value / share
- $-16.50
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -2.59distress
- Accruals / assets
- −24.2%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 1 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Negative operating cash flow
- Strong return on equity (>15%)
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Janus Henderson Group PlcPassive (13G)Feb 17, 2026
- Fmr LlcPassive (13G)Nov 17, 2025
- Arch Venture Fund Xii, L.P.Activist (13D)Nov 14, 2025
- Population Health Partners Gp, LlcPassive (13G)Nov 13, 2025
- Vanguard Group IncPassive (13G)Oct 31, 2025
- Validae Health, L.P.Passive (13G)Jun 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Fmr Llc10% owner | Nov 13, 2025 | J | 3,010 | — |
| Arch Venture Partners Xii, LlcDirector | Nov 13, 2025 | D | 18.5M | — |
| Marso StevenOfficer — CHIEF MEDICAL OFFICER | Nov 13, 2025 | D | 17,000 | — |
| Berns Paul LDirector | Nov 13, 2025 | D | 4,031 | — |
| Lang MatthewOfficer — CHIEF LEGAL OFFICER | Nov 13, 2025 | D | 12,500 | — |
| Population Health Partners Gp, Llc10% owner | Nov 13, 2025 | D | 127,675 | — |
| Burow KristinaDirector | Nov 13, 2025 | D | 2,688 | — |
| Validae Health, L.P.10% owner | Nov 11, 2025 | J | 12.8M | $0.00 |
| Pinto JoshuaDirector | Nov 13, 2025 | D | 2,688 | — |
| Stonehouse Jon PDirector | Nov 13, 2025 | D | 2,688 | — |
| Hubbard BrianOfficer — CHIEF SCIENTIFIC OFFICER | Nov 13, 2025 | D | 17,000 | — |
| Visioli ChristopherOfficer — CHIEF FINANCIAL OFFICER | Nov 13, 2025 | D | 21,250 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Oct 31, 2025 | 4.8M | 2.5 | -2.1% |
| Oct 15, 2025 | 4.9M | 2.8 | -24.8% |
| Sep 30, 2025 | 6.5M | 1.3 | -25.1% |
| Sep 15, 2025 | 8.6M | 5.6 | -5.2% |
| Aug 29, 2025 | 9.1M | 6.9 | -5.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Shareholder vote · Other material eventNov 13, 2025
- Entered a material agreement · Other material eventNov 10, 2025
- Other material eventNov 6, 2025
- Other material eventNov 4, 2025
- Other material eventNov 3, 2025
- Other material eventNov 3, 2025
- Other material eventOct 30, 2025
- Regulation FD disclosure · Other material eventSep 29, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AFeb 17, 2026
- 15-12GNov 24, 2025
- SCHEDULE 13G/ANov 17, 2025
- 4Nov 17, 2025
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESNov 14, 2025
- SCHEDULE 13D/ANov 14, 2025
- SCHEDULE 13GNov 14, 2025
- SCHEDULE 13G/ANov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
- 4Nov 13, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.